Juan Rigoberto Tejedo Huaman-rekin lankidetzan egindako argitalpenak (3)

2020

  1. Corrigendum: Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus (Frontiers in Immunology, (2019), 10, 10.3389/fimmu.2019.01151)

    Frontiers in Immunology

2019

  1. Cost-effective, safe, and personalized cell therapy for critical limb ischemia in type 2 diabetes mellitus

    Frontiers in Immunology, Vol. 10, Núm. JUN

2013

  1. Zebularine regulates early stages of mESC differentiation: Effect on cardiac commitment

    Cell Death and Disease, Vol. 4, Núm. 4